Seeking Alpha

Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting...

Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)